The complaint filed against the NASDAQ-listed firm centers on violations of the Securities Exchange Act of 1934. According to the court filings, ADMA purportedly engaged in "channel stuffing"—a practice used to artificially inflate sales activity—while simultaneously failing to report significant related-party deals. These omissions allegedly rendered the company’s public disclosures materially false and misleading to market participants.
In section Releases
ADMA Biologics Faces Class Action Over Alleged Securities Fraud
Investors who held ADMA Biologics stock between August 9, 2024, and March 25, 2026, are facing a critical August 10 deadline to join a class action lawsuit. The litigation alleges that the company misled shareholders by inflating sales figures and concealing undisclosed related-party transactions throughout the specified period.
The DJS Law Group is currently representing the interests of affected shareholders, seeking to recover losses sustained during the class period. While the firm is soliciting lead plaintiffs, participation in potential recoveries does not strictly require an official appointment in that role. Shareholders seeking to participate in the litigation may reach the firm at 914-206-9742 or via their Eastchester, New York office.
Comments (0)
No comments yet. Be the first!